Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurogen (NRGN) -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (255)	2/12/2000 4:27:00 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 523

<<I'm glad I am now looking at companies myself, rather than mutuals.>> Look deep. When you reach bottom let us know what did you find. Maybe, than will not seams as odd? Miljenko

To: Jim Oravetz who wrote (255)	2/12/2000 6:01:00 PM
From: Miljenko Zuanic	Respond to of 523

One more thing, For the start you can check their NEW web site. Finally they did update and modernize it. Lot of info for start. Bravo! Next is new CRO and aggressive business model, so all should know what is going on at this sleeper. Miljenko

To: Jim Oravetz who wrote (255)	5/12/2000 12:49:00 PM
From: Jim Oravetz	Respond to of 523

Neurogen Corp. - 1st Quar March 31: 2000 1999 Revenue $2,841,000 $2,636,000 Net income a (10,669,000) (3,406,000) Avg shrs (basic) 15,297,000 14,548,000 Avg shrs (diluted) 15,297,000 14,548,000 Shr earns (basic) Net income a (.70) (.23) Shr earns (diluted) Net income a (.70) (.23) a. Includes a noncash compensation charge of $6.5 million related to the performance of restricted stock previously granted to employees. Excluding charges, losses were $4.17 million, or 27 cents a share.